Hanover

• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi … Ended recruitment
  2023-509516-28-00 4 2021-02-22 Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III col
• A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 … Ended recruitment
  2024-512232-30-00 10 2021-01-18 Primary Biliary Cholangitis
• A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa … Ended recruitment
  2023-506911-16-00 5 2020-12-04 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTAT
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca … Ended recruitment
  2024-516653-44-00 5 2020-11-30 HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed
• Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® co … Ended recruitment
  2024-518033-28-00 6 2020-11-27 Prophylaxis of transplant rejection in adult liver allograft recipient
• An extension study to learn if bepranemab (UCB0107) is safe over a long period in adults with progressive supranuclear palsy Ended recruitment
  2024-510951-36-00 3 2020-11-16 Progressive Supranuclear Palsy
• A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung … Ended recruitment
  2024-511185-37-00 6 2020-11-03 Completely resected stage I or IIA non-squamous non-small cell lung ca
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc … Ended recruitment
  2023-506515-18-00 5 2020-10-23 Primary Progressive Multiple Sclerosis (PPMS)
• Treatment of advanced-stage malignancies harboring BRAF mutations with combination of Sorafenib and Trametinib: a multicenter study Ended recruitment
  2024-512887-77-00 9 2020-10-21 advanced-stage malignancies harboring BRAF mutations with impaired kin
• Long-term need of Ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due … Ended recruitment
  2023-507816-11-00 5 2020-08-17 Macular edema due to central retinal vein occlusion
• A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn’s Disease (VIVID-2) Ended recruitment
  2022-502841-91-00 5 2020-08-12 Crohn’s Disease
• A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi … Ended recruitment
  2023-509242-35-00 5 2020-07-23 HR+/HER2- early breast cancer
• A Phase 3 study to compare long-term efficacy and safety of macitentan 75 mg versus 10 mg in Pulmonary Arterial Hypertension. Ended recruitment
  2024-515669-32-00 5 2020-06-30 Pulmonary arterial hypertension
• Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2 … Ended recruitment
  2023-505042-25-00 5 2020-05-05 Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
• A Phase 3 Trial Comparing Selpercatinib to Cabozantinib or Vandetanib in Patients with RET-Mutant Medullary Thyroid Cancer Ended recruitment
  2023-506782-56-00 5 2020-03-10 RET-Mutant Medullary Thyroid Cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• IMMUWHY Ended recruitment
  2023-508314-42-00 4 2020-02-27 Advanced stage intrahepatic biliary tract cancer (BTC)
• A Study to Assess the Safety, Tolerability and Immunological Response of ASP2390 in Adult Subjects Allergic to House Dust Mites Ended recruitment
  2022-500660-35-00 1 2020-02-17 Allergy to House Dust Mites
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Ulcerative Colitis Ended recruitment
  2023-504718-31-00 10 2019-10-19 Moderately to Severely Active Ulcerative Colitis
• Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno … Ended recruitment
  2023-503670-21-00 5 2019-08-28 Patients with newly diagnosed AML and intermediate- or adverse-risk ge

Showing 385–408 of 582 trials